COST-EFFECTIVENESS OF USING DETEMIR IN TYPE 2 DIABETES WITH THE RISK OF CARDIOVASCULAR EVENTS AND DEATH

被引：0
|
作者：
Romero, M. [1 ]
Chavez, D. [1 ]
Karpf, E. [1 ]
Alvis, N. [2 ]
机构：
[1] Fdn Salutia, Bogota, Colombia
[2] Univ Cartagena, Cartagena De Indias, Bolivar, Colombia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1591
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A547 / A547
页数：1
相关论文
共 50 条
  • [21] ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL
    McEwan, P.
    Evans, L. M.
    Bergenheim, K.
    VALUE IN HEALTH, 2010, 13 (07) : A293 - A293
  • [22] COST-EFFECTIVENESS OF EXERCISE PROGRAMS IN TYPE 2 DIABETES
    Coyle, Doug
    Coyle, Kathryn
    Kenny, Glen P.
    Boule, Normand G.
    Wells, George A.
    Fortier, Michelle
    Reid, Robert D.
    Phillips, Penny
    Sigal, Ronald J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (03) : 228 - 234
  • [23] Cost-effectiveness of atorvastatin 10 mg daily in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada
    Khoury, Hanane
    Wagner, Monika
    Merikle, Elizabeth
    Johnson, Scott J.
    Roberts, Craig
    CIRCULATION, 2008, 117 (21) : E450 - E450
  • [24] Cost-effectiveness of ramipril in preventing cardiovascular events in high-risk patients
    Ganguly, R
    Parasuraman, TV
    VALUE IN HEALTH, 2003, 6 (03) : 321 - 322
  • [25] Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: A Swiss perspective
    Sendi, P
    Russ, W
    Battegay, E
    Bucher, H
    VALUE IN HEALTH, 2004, 7 (06) : 693 - 693
  • [26] Cost-effectiveness of insulin detemir: a systematic review
    Suh, Dong-Churl
    Aagren, Mark
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (06) : 641 - 655
  • [27] COST-EFFECTIVENESS OF THE INTRODUCTION OF A RISK STRATIFIED POPULATION SCREENING FOR TYPE 2 DIABETES IN HUNGARY
    Zsolyom, A.
    Nagy, B.
    Dessewffy, Z.
    Steiner, T.
    Kalo, Z.
    Voko, Z.
    VALUE IN HEALTH, 2014, 17 (03) : A259 - A259
  • [28] Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes
    Nagy, Balazs
    Zsolyom, Adriana
    Nagyjanosi, Laszlo
    Meresz, Gergo
    Steiner, Tamas
    Papp, Eszter
    Dessewffy, Zoltan
    Jermendy, Gyorgy
    Winkler, Gabor
    Kalo, Zoltan
    Voko, Zoltan
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (07) : 710 - 729
  • [29] Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
    Sehested, Thomas S. G.
    Bjerre, Jenny
    Ku, Seul
    Chang, Andrew
    Jahansouz, Alison
    Owens, Douglas K.
    Hlatky, Mark A.
    Goldhaber-Fiebert, Jeremy D.
    JAMA CARDIOLOGY, 2019, 4 (02) : 128 - 135
  • [30] Cost-effectiveness of canakinumab to prevent recurrent cardiovascular events
    Sehested, T. S. G.
    Bjerre, J.
    Chang, A.
    Ku, S.
    Jahansouz, A.
    Owens, D. K.
    Hlatky, M. A.
    Goldhaber-Fiebert, J. D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 503 - 504
12345